Carregant...
Treatment of walking impairment in multiple sclerosis with dalfampridine
Potassium channel blockade has long been considered a potential therapeutic strategy for treatment of multiple sclerosis (MS) based on the pathophysiology of demyelinated axons. Dalfampridine, which is also known as fampridine or 4-aminopyridine (4-AP), is the potassium channel blocker that has been...
Guardat en:
Autor principal: | |
---|---|
Format: | Artigo |
Idioma: | Inglês |
Publicat: |
SAGE Publishing
2011-03-01
|
Col·lecció: | Therapeutic Advances in Neurological Disorders |
Accés en línia: | https://doi.org/10.1177/1756285611403960 |
Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|